PTC Therapeutics PTCT Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash

Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash at other companies

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

See full

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

See full

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

See full

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash?: PTC Therapeutics (PTCT) reported effect of currency exchange rate changes on cash, cash equivalents, and restricted cash of -$1.52M in Q1 2026.
How has PTC Therapeutics's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash changed year-over-year?: PTC Therapeutics's effect of currency exchange rate changes on cash, cash equivalents, and restricted cash decreased by 128.3% year-over-year, from $5.39M to -$1.52M.